PDAC Clinical Trials

25 clinical trials for PDAC across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE3
• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE2
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) — RECRUITING · PHASE3
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE3
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — RECRUITING · PHASE1
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE3
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — RECRUITING · PHASE1
• Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC — RECRUITING · PHASE1
• Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals — RECRUITING · PHASE1
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients — RECRUITING · PHASE1
• A Prospective Registry for Patients at High-Risk for Pancreatic Cancer — RECRUITING
• IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation — RECRUITING · PHASE1
• Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer — RECRUITING · NA
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — OTHER
• ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — ACTIVE_NOT_RECRUITING · PHASE3
• The Canopy Cancer Collective Clinical Registry Protocol — NOT_YET_RECRUITING
• Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) — ACTIVE_NOT_RECRUITING · PHASE1
• A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors — NOT_YET_RECRUITING · PHASE1
• Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC — WITHDRAWN · PHASE1
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer — TERMINATED · PHASE1
• Mesopancreas Study in Pancreatic Cancer — NOT_YET_RECRUITING
• Pancreatic Cancer Recurrence in the Netherlands — OTHER
• 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma — OTHER · NA

Refine this search